In vitro assessment of the dual-targeting behavior of a peptide-based magnetic resonance imaging contrast agent

International Journal of Molecular Medicine

Volumn 33, Issue 1, 2014, Pages 215-220

  Yang, Yuping ^a,b   Yu, Kaichao ^a   Zhang, Hailu ^b   Dai, Jianwu ^b,c   Deng, Zongwu ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SUZHOU INSTITUTE OF NANO TECH AND NANO BIONICS   (China)

^c INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY   (China)

Author keywords

Arg Gly Asp; Asn Gly Arg; Dual targeting; Magnetic resonance imaging contrast agent

Indexed keywords

ARGININE; ARGINYLGLYCYLASPARTIC ACID; GADOLINIUM COMPLEX S8; GADOLINIUM PENTETATE MEGLUMINE; GADOTERIC ACID; MICROSOMAL AMINOPEPTIDASE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

AMINO ACID SEQUENCE; ARTICLE; BREAST CANCER; CANCER CELL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MAGNETIC FIELD; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN MOTIF;

ANTIGENS, CD13; BREAST NEOPLASMS; CELL LINE, TUMOR; CONTRAST MEDIA; FEMALE; HUMANS; INTEGRIN ALPHAVBETA3; MAGNETIC RESONANCE IMAGING; MALE; OLIGOPEPTIDES; PROSTATIC NEOPLASMS;

EID: 84892767515     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1551     Document Type: Article

References (26)

1. Riccabona G and Decristoforo C: Peptide targeted imaging of cancer. Cancer Biother Radiopharm 18: 675-687, 2003.
2. Rudin M and Weissleder R: Molecular imaging in drug discovery and development. Nat Rev Drug Discov 2: 123-131, 2003.
3. Li ZJ and Cho CH: Peptides as targeting probes against tumor vasculature for diagnosis and drug delivery. J Transl Med 10 (Suppl 1): S1, 2012.
4. Caravan P: Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action. Acc Chem Res 42: 851-862, 2009.
5. Mitra A, Nan A, Papadimitriou JC, et al: Polymer-peptide conjugates for angiogenesis targeted tumor radiotherapy. Nucl Med Biol 33: 43-52, 2006.
6. Pawar PV, Gohil SV, Jain JP, et al: Functionalized polymersomes for biomedical applications. Polym Chem 4: 3160-3176, 2013.
7. Seward GK, Wei Q and Dmochowski IJ: Peptide-mediated cellular uptake of cryptophane. Bioconjug Chem 19: 2129-2135, 2008.
8. Ye F, Wu X, Jeong EK, Jia Z, et al: A peptide targeted contrast agent specific to fibrin-fibronectin complexes for cancer molecular imaging with MRI. Bioconjug Chem 19: 2300-2303, 2008.
9. Chen XM, Wang X, Huang Y, et al: A comparison study of the targeting properties of NGR liposomes and RGD-liposomes towards human umbilical vein endothelial cells. J Chinese Pharm Sci 18: 162-169, 2009.
10. Beer AJ and Schwaiger M: Imaging of integrin alphavbeta3 expression. Cancer Metastasis Rev 27: 631-644, 2008.
11. Liu S: Radiolabeled cyclic RGD peptides as integrin alpha(v) beta(3)-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug Chem 20: 2200-2213, 2009.
12. Dijkgraaf I, Kruijtzer JA, Liu S, et al: Improved targeting of the alpha(v)beta(3) integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol Imaging 34: 267-273, 2007.
13. Haukkala J, Laitinen I, Luoto P, et al: 68Ga-DOTA-RGD peptide: biodistribution and binding into atherosclerotic plaques in mice. Eur J Nucl Med Mol Imaging 36: 2058-2067, 2009.
14. 4 nanoparticles and their specific targeting to integrin alpha(v)beta3-rich tumor cells. J Am Chem Soc 130: 7542-7543, 2008.
15. Wang RE, Niu Y, Wu H, et al: Development of NGR peptide-based agents for tumor imaging. Am J Nucl Med Mol Imaging 1: 36-46, 2011.
16. 13. Bioorg Med Chem 19: 1434-1449, 2011.
17. 13/APN identified through peptide array screening resemble fibronectin sequences. ACS Comb Sci: Oct 11, 2012 (Epub ahead of print).
18. Negussie AH, Miller JL, Reddy G, et al: Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome. J Control Celease 143: 265-273, 2010.
19. Sloan EK, Pouliot N, Stanley KL, et al: Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res 8: R20, 2006.
20. 3 integrin-targeted tumor imaging (MRI). Inorg Chem 52: 1701-1709, 2013.
21. Ndinguri MW, Solipuram R, Gambrell RP, et al: Peptide targeting of platinum anti-cancer drugs. Bioconjug Chem 20: 1869-1878, 2009.
22. Mishra AK and Chatal JF: Synthesis of macrocyclic bifunctional chelating agents: 1,4,7-tris(carboxymethyl)-10-(2-amino ethyl)-1,4,7,10- tetraazacyclododecane and 1,4,8-tris (carboxymethyl)-11-(2-aminoethyl)-1,4,8,11- tetraazacyclotetradecane. New J Chem 25: 336-339, 2001.
23. Kates SA, Sole NA, Johnson CR, et al: A novel, convenient, 3-dimensional orthogonal strategy for solid-phase synthesis of cyclic-peptides. Tetrahedron Lett 34: 1549-1552, 1993.
24. Sarin VK, Kent SBH, Tam JP and Merrifield RB: Quantitative monitoring of solid-phase peptide synthesis by the ninhydrin reaction. Anal Biochem 117: 147-157, 1981.
25. Dathe M, Nikolenko H, Klose J and Bienert M: Cyclization increases the antimicrobial activity and selectivity of arginine- and tryptophan-containing hexapeptides. Biochemistry 43: 9140-9150, 2004.
26. Colombo G, Curnis F, De Mori GM, et al: Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J Biol Chem 277: 47891-47897, 2002.